Summit Therapeutics, Inc. (SMMT)
16.76
+0.06
(+0.39%)
USD |
NASDAQ |
Oct 02, 16:00
16.75
0.00 (0.00%)
After-Hours: 20:00
Summit Therapeutics EPS Diluted (Quarterly) : -0.2772 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2772 |
| March 31, 2026 | -0.2443 |
| December 31, 2025 | -0.286 |
| September 30, 2025 | -0.3118 |
| June 30, 2025 | -0.7618 |
| March 31, 2025 | -0.0852 |
| December 31, 2024 | -0.083 |
| September 30, 2024 | -0.0774 |
| June 30, 2024 | -0.0853 |
| March 31, 2024 | -0.0619 |
| December 31, 2023 | -0.0522 |
| September 30, 2023 | -0.0305 |
| June 30, 2023 | -0.0211 |
| March 31, 2023 | -1.434 |
| December 31, 2022 | -0.0911 |
| September 30, 2022 | -0.1439 |
| June 30, 2022 | -0.1683 |
| March 31, 2022 | -0.2182 |
| December 31, 2021 | -0.2764 |
| September 30, 2021 | -0.2011 |
| June 30, 2021 | -0.2693 |
| March 31, 2021 | -0.2112 |
| December 31, 2020 | -0.164 |
| September 30, 2020 | -0.2639 |
| June 30, 2020 | -0.2273 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.0128 |
| January 31, 2020 | 0.00 |
| October 31, 2019 | 0.00 |
| July 31, 2019 | 0.00 |
| April 30, 2019 | 0.00 |
| January 31, 2019 | -0.065 |
| October 31, 2018 | -0.1286 |
| July 31, 2018 | 0.4287 |
| April 30, 2018 | -0.1069 |
| January 31, 2018 | -0.2067 |
| October 31, 2017 | -0.0172 |
| July 31, 2017 | -0.0645 |
| April 30, 2017 | -0.0999 |
| January 31, 2017 | -0.0993 |
| October 31, 2016 | -0.09 |
| July 31, 2016 | -0.1395 |
| April 30, 2016 | -0.1285 |
| January 31, 2016 | -0.1188 |
| October 31, 2015 | -0.1233 |
| July 31, 2015 | -0.1087 |
| April 30, 2015 | -0.0905 |
| January 31, 2015 | -0.1086 |
| October 31, 2014 | 0.00 |
| July 31, 2014 | 0.00 |
| April 30, 2014 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0017 |
| Brainstorm Cell Therapeutics, Inc. | -0.3494 |
| Kezar Life Sciences, Inc. | -0.7838 |
| Protara Therapeutics, Inc. | -0.3552 |
| Clene, Inc. | -1.084 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -215.70M |
| Total Expenses (Quarterly) | 215.70M |
| Enterprise Value | 12.62B |
| Earnings Yield | -6.68% |
| Normalized Earnings Yield | -6.680 |